methionine has been researched along with 6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arora, S; Chaturvedi, A; Heuser, M; Joshi, G; Kumar, R; Patil, S | 1 |
| Lai, X; Wu, H; Yang, SH; Yi, ZJ | 1 |
2 other study(ies) available for methionine and 6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone
| Article | Year |
|---|---|
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
Topics: Allosteric Regulation; Allosteric Site; Carrier Proteins; Chemistry, Pharmaceutical; Glycolysis; Humans; Membrane Proteins; Protein Kinase Inhibitors; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2022 |
The PKM2 activator TEPP-46 attenuates MCD feeding-induced nonalcoholic steatohepatitis by inhibiting the activation of Kupffer cells.
Topics: Animals; Choline; Cytokines; Diet; Inflammasomes; Kupffer Cells; Liver; Male; Methionine; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Non-alcoholic Fatty Liver Disease; Pyridazines; Pyrroles; Pyruvate Kinase | 2021 |